Farnesyl transferase inhibitors in the treatment of breast cancer.

摘要: Until recently, the therapeutic treatment of breast cancer has been dominated by endocrine-based drugs (oestrogen receptor antagonists, aromatase inhibitors etc.) and conventional cytotoxics (doxorubicin, cyclophosphamide, 5fluorouracil etc.). However, advent new generation signal transduction inhibitor targeted against molecular abnormalities (e.g., antibody trastuzumab, directed cERBB2 receptor) promise providing a era more tumour selective therapy. Inhibitors enzyme farnesyl transferase (FTIs) are now undergoing early-stage clinical trials, including in patients with advanced cancer. Although originally developed as RAS pathways, it is apparent that these better described prenylation inhibitors; addition 15-carbon prenyl or moiety being critical to function number proteins, RAS. At least three FTIs curren...